Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Retatrutide, originally developed by Eli Lilly, has found a loyal fan base—even though clinical trials of the drug still ...

The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector currently ...

Eli Lilly's experimental drug, retatrutide, showed strong results in a late-stage trial, helping patients lose nearly 29% of ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in ...

San Francisco-based pharmaceutical company OKAVA is investigating an implant that slowly releases a GLP-1 medication for up ...

Women with polycystic ovary syndrome are increasingly turning to blockbuster weight-loss drugs from Eli Lilly and Novo ...

The World Health Organization issued new guidance this week on the use of popular GLP-1 drugs, like Ozempic, Wegovy, Mounjaro ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

Some patients dropped out of the trial early because they had lost so much weight.